SEC Connect
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 23, 2017
CHROMADEX CORPORATION
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-53290
|
26-2940963
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
10005
Muirlands Boulevard, Suite G, Irvine, California,
92618
(Address
of principal executive offices, including zip code)
(949)
419-0288
(Registrant's
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[
]Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[
]Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[
]Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[
]Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
On
February 23, 2017, ChromaDex Corporation (the
“Company”) issued a press release of the Chief
Executive Officer’s letter to the shareholders of the
Company. A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated by reference in this
Current Report.
The
information in this Item 8.01 and the exhibit hereto are being
furnished and shall not be deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to
the liability of that section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
The
press release attached as Exhibit 99.1 contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Exchange Act, including
statements related to future commercial opportunities for
NIAGEN®, whether www.aboutnr.com will become the
scientifically-validated, information hub for nicotinamide riboside
(“NR”) and nicotinamide adenine dinucleotide
(“NAD+”) education, the ability of NR to increase
production of NAD+, whether NIAGEN® will become the next
blockbuster ingredient, whether the number of collaborative
research studies for NIAGEN® will increase, the timing and
results of future studies, whether positive data from clinical
studies will result in business development deals and revenue
opportunities, the potential for NIAGEN® to be used in
pharmaceutical applications, the timing and results of future
regulatory filings in the U.S. and other countries, unaudited
financial results, whether human studies will grow the customer
base to include large mainstream consumer product companies, and
whether NIAGEN® will be included in consumer products in
certain consumer segments. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's Annual
Report on Form 10-K for the fiscal year ended January 2, 2016, the
Company's Quarterly Reports on Form 10-Q and other filings
submitted by the Company to the SEC, copies of which may be
obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and the
Company undertakes no obligation to revise or update the press
release to reflect events or circumstances after the date
hereof.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press
Release, dated February 23, 2017
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Dated:
February 23, 2017
|
|
CHROMADEX CORPORATION
By:
/s/ Frank L. Jaksch,
Jr.
Name: Frank L. Jaksch, Jr.
Title: Chief Executive Officer
|
INDEX TO EXHIBITS
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press
Release, dated February 23, 2017
|
|
|
|
|